The cholinergic agonist RS 86: a pharmacopsychological study.
The cholinergic-adrenergic balance hypothesis of affective disorders postulates noradrenergic over-activity and cholinergic hypoactivity in mania and the converse in depression. Some evidence for cholinergic contributions to mood regulation derives from the antimanic and depressiogenic activity of physostigmine and arecoline. However, both drugs have pharmacodynamic and pharmacokinetic disadvantages. Therefore, the orally active muscarinic agonist RS 86 was tested in a double-blind dose-response study for its psychotropic effects in one healthy volunteer. A dose-dependent anergic-anhedonic syndrome was identified in comparison to placebo. The study confirms the physostigmine syndrome to be mediated by muscarinic, possibly M1 receptors, and gives further support to the hypothesis of a cholinergic modulation of mood and behavior in man.
Fritze
J
J
Department of Psychiatry, University of Würzburg, FRG.
Beckmann
H
H
D000339:Affect / Q000187:drug effects*; D001143:Arousal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D009042:Motivation / Q000187:drug effects; D011581:Psychological Tests; D011897:Random Allocation; D011950:Receptors, Cholinergic / Q000187:drug effects*; D011976:Receptors, Muscarinic / Q000187:drug effects; D013388:Succinimides / Q000494:pharmacology*
D011950:Receptors, Cholinergic; D011976:Receptors, Muscarinic; D013388:Succinimides; C001886:2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione